Brought to you by 
Syndax signs up Ventana to develop companion diagnostic for entinostat
20 Jan 2012
Executive Summary
Ventana Medical Systems Inc., a division of Roche Diagnostics Corp. that focuses on anatomical pathology markets, has agreed to develop for Syndax Pharmaceuticals Inc. (cancer medicines targeting epigenetics) a companion diagnostic to select a unique patient population for treatment with erlotinib (Roche’s Tarceva) and Syndax’s lead candidate entinostat, which is about to enter Phase III for non-small cell lung cancer.
Deal Industry
- In Vitro Diagnostics
- Pharmaceuticals
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com